OxyContin 40mg is a brand-name extended-release formulation of oxycodone hydrochloride, a potent opioid analgesic. The 40mg strength refers to tablets containing 40 milligrams of oxycodone per dose, designed for once every 12 hours administration in opioid-tolerant patients for management of moderate to severe chronic pain (e.g., cancer pain or post-surgical). It’s not for acute pain or opioid-naive patients due to high overdose risk.

Key Facts and Evidence

• Pharmacology: Oxycodone is a semi-synthetic opioid agonist binding to mu-opioid receptors in the brain and spinal cord, inhibiting pain signals. Extended-release uses a polymer matrix for slow dissolution, providing steady blood levels (peak at 3-4 hours, half-life ~4.5 hours). Source: FDA prescribing information (Purdue Pharma, updated 2023).
• Appearance: White, round, film-coated tablets imprinted “OP 40” (reformulated abuse-deterrent version since 2010 crushes into gel, reducing misuse potential). Evidence: Confirmed via Purdue Pharma product specs and DEA scheduling docs.
• Dosing Guidelines (for adults, opioid-tolerant):

• Conversion: 40mg OxyContin ≈ 60mg oral morphine equivalents daily. Use FDA equianalgesic tables for accuracy.
• Bioavailability: ~60-87% oral; food increases absorption slightly. CYP3A4/2D6 metabolism; genetic poor metabolizers at higher overdose risk (studies in Clin Pharmacol Ther, 2015).

Clinical Use and Efficacy

• Indications: Persistent pain requiring around-the-clock opioids (e.g., ≥5/10 pain score). RCTs (e.g., Pain journal, 2004) show superior pain control vs. placebo for 12 weeks in chronic back pain.
• Effectiveness Data: In trials, 40mg q12h reduced pain by 30-50% in 60% of patients vs. 20% placebo (Cochrane review, 2017). Long-term: Tolerance develops in 20-30% within months.

Risks and Side Effects

High abuse potential (Schedule II controlled substance). Facts backed by CDC and NIH data:

• Addiction/Overdose: 2019 CDC data links extended-release oxycodone to 15% of U.S. opioid deaths. Naloxone reverses OD (FDA-approved).
• Contraindications: Acute asthma, paralytic ileus, recent MAOIs. Avoid with alcohol/benzos (respiratory arrest risk triples per JAMA 2017).
• Withdrawal: Symptoms peak 72 hours post-last dose (sweats, anxiety); taper 10-25% weekly.

Abuse and Street Context

• Street Value: $1-2 per 40mg pill (DEA 2023 estimates), often crushed/snorted despite abuse-deterrent tech (success rate dropped 80% post-2010 per NEJM 2012).
• Detection: Urine tests positive 1-4 days; blood 24 hours. Fentanyl-laced fakes common (DEA alerts).

Warnings: Only use under prescription. Misuse causes 50,000+ U.S. deaths/year (CDC 2022). Consult MD for personalized advice; this is factual info from FDA/DEA/NIH sources, not medical advice. For cessation, SAMHSA helpline: 1-800-662-HELP.